Compile Data Set for Download or QSAR
Report error Found 416 Enz. Inhib. hit(s) with all data for entry = 12388
TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699923(US20240335442, Compound 20)
Affinity DataIC50: 13.3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700007(US20240335442, Compound 108)
Affinity DataIC50: 17.7nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700092(US20240335442, Compound 198)
Affinity DataIC50: 24nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699926(US20240335442, Compound 26)
Affinity DataIC50: 24.9nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699918(US20240335442, Compound 15)
Affinity DataIC50: 25.2nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699915(US20240335442, Compound 12)
Affinity DataIC50: 25.6nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699925(US20240335442, Compound 22)
Affinity DataIC50: 27.2nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700007(US20240335442, Compound 108)
Affinity DataIC50: 30.8nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699984(US20240335442, Compound 85)
Affinity DataIC50: 31.8nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699911(US20240335442, Compound 2)
Affinity DataIC50: 32.5nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700004(US20240335442, Compound 105)
Affinity DataIC50: 33.7nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699987(US20240335442, Compound 88)
Affinity DataIC50: 42.6nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700004(US20240335442, Compound 105)
Affinity DataIC50: 44.6nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700047(US20240335442, Compound 148)
Affinity DataIC50: 48.5nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700022(US20240335442, Compound 123)
Affinity DataIC50: 49.2nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699974(US20240335442, Compound 75)
Affinity DataIC50: 51.2nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699928(US20240335442, Compound 29)
Affinity DataIC50: 51.3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699929(US20240335442, Compound 30)
Affinity DataIC50: 55.6nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700048(US20240335442, Compound 149)
Affinity DataIC50: 60.9nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699921(US20240335442, Compound 18)
Affinity DataIC50: 62.6nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699928(US20240335442, Compound 29)
Affinity DataIC50: 63.1nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700047(US20240335442, Compound 148)
Affinity DataIC50: 69.1nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700095(US20240335442, Compound 201)
Affinity DataIC50: 70nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699987(US20240335442, Compound 88)
Affinity DataIC50: 70.4nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699916(US20240335442, Compound 13)
Affinity DataIC50: 73nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700023(US20240335442, Compound 124)
Affinity DataIC50: 73.2nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699931(US20240335442, Compound 32)
Affinity DataIC50: 73.9nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699924(US20240335442, Compound 21)
Affinity DataIC50: 74.5nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700017(US20240335442, Compound 118)
Affinity DataIC50: 79.9nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699946(US20240335442, Compound 47)
Affinity DataIC50: 82nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700005(US20240335442, Compound 106)
Affinity DataIC50: 83nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699938(US20240335442, Compound 39)
Affinity DataIC50: 86.4nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700051(US20240335442, Compound 152)
Affinity DataIC50: 88.4nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700005(US20240335442, Compound 106)
Affinity DataIC50: 90.2nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700096(US20240335442, Compound 202)
Affinity DataIC50: 93nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699919(US20240335442, Compound 16)
Affinity DataIC50: 93.3nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699922(US20240335442, Compound 19)
Affinity DataIC50: 93.5nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699940(US20240335442, Compound 41)
Affinity DataIC50: 94.5nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699932(US20240335442, Compound 33)
Affinity DataIC50: 96.8nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699957(US20240335442, Compound 58)
Affinity DataIC50: 97nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699915(US20240335442, Compound 12)
Affinity DataIC50: 98nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699929(US20240335442, Compound 30)
Affinity DataIC50: 102nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699982(US20240335442, Compound 83)
Affinity DataIC50: 103nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700096(US20240335442, Compound 202)
Affinity DataIC50: 107nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700073(US20240335442, Compound 175)
Affinity DataIC50: 110nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM699936(US20240335442, Compound 37)
Affinity DataIC50: 115nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700019(US20240335442, Compound 120)
Affinity DataIC50: 116nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700106(US20240335442, Compound 215)
Affinity DataIC50: 116nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700020(US20240335442, Compound 121)
Affinity DataIC50: 117nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

TargetSodium channel protein type 8 subunit alpha(Human)
Eurofarma

US Patent
LigandPNGBDBM700049(US20240335442, Compound 150)
Affinity DataIC50: 118nMAssay Description:Compounds of Formula (I), were diluted in eight concentrations in the extracellular solution composed of physiological saline, buffered with HEPES (m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2025
Entry Details
US Patent

Displayed 1 to 50 (of 416 total ) | Next | Last >>
Jump to: